Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04176991|
Recruitment Status : Completed
First Posted : November 26, 2019
Last Update Posted : November 12, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Friedreich Ataxia||Biological: CTI-1601 Biological: Placebo||Phase 1|
Single Ascending Dose (SAD), Double-Blind, Placebo Controlled Study.
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in subjects with Friedreich's ataxia.
- To evaluate the pharmacokinetics (PK) of CTI-1601 following increasing single doses of subcutaneously (SC) administered CTI-1601.
- To evaluate the pharmacodynamics (PD) of CTI-1601 following increasing single doses of SC administered CTI-1601.
CTI-1601 or Placebo - Dose/Mode of Administration: Single Dose/Subcutaneous
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||28 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia|
|Actual Study Start Date :||December 11, 2019|
|Actual Primary Completion Date :||October 31, 2020|
|Actual Study Completion Date :||October 31, 2020|
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
|Placebo Comparator: Placebo||
- Number of Participants with Treatment-Emergent Adverse Events [ Time Frame: Through study completion, an average of 70 days ]Overall summary of the Participants with Treatment Emergent Adverse Events
- Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term [ Time Frame: Through study completion, an average of 70 days ]Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 22.0)
- Pharmacokinetics - Area under the concentration-time curve after a single dose [ Time Frame: Up to 48 hours ]Summary assessment of changes in the area under the concentration-time curve after a single dose
- Pharmacokinetics - Maximum observed plasma concentration after a single dose [ Time Frame: Up to 48 hours ]Summary assessment of changes in the maximum observed plasma concentration after a single dose
- Pharmacokinetics - Time to reach maximum plasma concentration after a single dose [ Time Frame: Up to 48 hours ]Summary assessment of changes in time to reach maximum plasma concentration after a single dose
- Pharmacokinetics - Area under the concentration-time curve from time 0 to infinity [ Time Frame: 48 hours ]Summary assessment of changes in the area under the concentration-time curve from time 0 to infinity
- Pharmacokinetics - Area under the concentration-time curve from time 0 to the last measurable time point [ Time Frame: 48 hours ]Summary assessment of changes in the Area under the concentration-time curve from time 0 to the last measurable time point
- Pharmacokinetics - Apparent total plasma clearance [ Time Frame: 48 hours ]Summary assessment of changes in the apparent total plasma clearance
- Pharmacokinetics - Terminal half-life estimation [ Time Frame: 48 hours ]Summary assessment of changes in the terminal half-life estimation
- Pharmacokinetics - Apparent volume of distribution [ Time Frame: 48 hours ]Summary assessment of changes in the apparent volume of distribution
- Changes from Baseline in Frataxin Levels in Buccal Cells [ Time Frame: At baseline and up to 10 days ]Summary assessment of changes in frataxin levels in buccal cells
- Changes from Baseline in Frataxin Levels in Whole Blood [ Time Frame: At baseline and up to 10 days ]Summary assessment of changes in frataxin levels in whole blood
- Changes in Gene Expression Profiling [ Time Frame: At baseline and up to 10 days ]Summary assessment of changes in gene expression levels
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Subject has genetically confirmed Friedreich's ataxia diagnosis, homozygous GAA repeat expansions, with repeat sizing (if available) included on diagnostic report.
- Subject is male or female, 18 years of age or older at screening.
- Subject must have a mFARS_neuro score ≥ 20 and be able to traverse a distance of 25 feet with or without some assistive device (cane, walker, crutches, self-propelled wheelchair) and (a) be able to sit upright with thighs together and arms crossed without requiring support on more than two sides; (b) be able to transfer from bed to chair independently or with minimal assistance if, in the opinion of the investigator, the degree of physical disability does not result in undue risk to the subject while participating in the study; and (c) perform basic daily care, such as feeding themselves and personal hygiene, with minimal assistance.
- Subjects must weigh > 40 kilograms (kg).
- Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only one allele) for Friedreich's ataxia.
- Subject requires use of amiodarone.
- Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to screening.
- Subject use of investigational drug (other than CTI-1601) or device within 90 days prior to screening.
- Subject use of daily biotin supplementation that exceeds 30 mcg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to study drug administration and/or throughout the entire study.
- Subject has clinically significant arrhythmia on electrocardiogram (ECG), or evidence of predisposition to significant ventricular arrhythmia on ECG, or evidence of active and unstable coronary artery disease.
- Male subject who has an ECG QTcF > 450 milliseconds or female subject who has an ECG QTcF > 470 milliseconds.
- Subject has a screening echocardiogram ejection fraction <45 percent.
- Subject has a history of aspiration, aspiration pneumonia, or recurrent episodes of pneumonia (greater than or equal to 2 episodes of pneumonia) within the last 12 months.
- Subjects with known or suspected chronic use of cannabinoid products.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04176991
|United States, New Jersey|
|Clinilabs Drug Development Corporation|
|Eatontown, New Jersey, United States, 07724|
|Responsible Party:||Larimar Therapeutics, Inc.|
|Other Study ID Numbers:||
|First Posted:||November 26, 2019 Key Record Dates|
|Last Update Posted:||November 12, 2020|
|Last Verified:||November 2020|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Nervous System Diseases
Central Nervous System Diseases
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn